Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Appropriate Antibiotic Use for Acute Otitis Media
Your Article Summary
Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx
Cancer, 06/30/09
Holsinger FC et al. - In a study to determine the long-term outcomes of pts with squamous cell carcinoma of the larynx and pharynx who were treated with platin-based exclusive chemotherapy (EC) after they achieved a complete clinical response (CCR) to induction chemotherapy, it was reported that for selected pts, EC may provide long-term, durable disease control. For pts who developed recurrent disease after EC, this approach did not diminish survival and maintained function in the majority of pts.
Methods- 142 who achieved a CCR after platin-based induction chemotherapy were treated exclusively with additional chemotherapy, and 98.6% were followed for a minimum of 3 yrs or until death.
- 35 pts had >10 yrs of follow-up.
- Survival rates at 1 yr and 5 yrs were 95.8% and 61.2%, respectively.
- The main causes of death were metachronous second primary tumors (n=27) and intercurrent disease (n=21).
- Death related to EC was not encountered, and only 2 pts (1.4%) had grade 4 toxicity.
- In multivariate analysis, primary tumor arising outside the glottic larynx and a Charlson comorbidity index >1 were associated with a statistically significant reduction in survival.
- 1-yr and 5-yr Kaplan-Meier local control estimates were 76.1% and 50.7%, respectively.
- Salvage treatment resulted in an observed final local control rate of 93% that varied from 97.2% in pts who had glottic cancer to 88.7% in pts who had tumor originating from other sites.
- Combined chemotherapy with cisplatin and 5-fluorouracil (PF) allowed for successful modulation of local therapy in 54.9% of pts.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer
Cochrane Reviews, 10/09/09
Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis
Allergy and Asthma Proceedings, 10/13/09
Otitis media and antihistamines
Current Allergy and Asthma Reports, 10/22/09
Today in Head and Neck...keeping you current
Receive free subspecialty "5-minute updates" via email
Consensus Statement on the Terminology and Classification of Central Neck Dissection for Thyroid Cancer
Thyroid, 11/02/09
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Annals of Oncology, 10/30/09
Diagnostic Pediatric Computed Tomographic Scans of the Head: Actual Dosage versus Estimated Risk
Plastic and Reconstructive Surgery, 10/12/09
Today in Larynx/Trachea/Airway...keeping you current
Receive free subspecialty "5-minute updates" via email
Thyroid lymphoma and airway obstruction – is there a rationale for surgical management?
International Journal of Clinical Practice, 10/19/09
Tracheostomy: from insertion to decannulation
Canadian Journal of Surgery, 10/08/09
Voice outcomes following repeated surgical resection of laryngeal papillomata in children
Otolaryngology Head and Neck Surgery, 10/14/09
Article Search
Sponsor


See Latest Articles


